Skip to main content
Clinical Trials/NCT03053518
NCT03053518
Terminated
Not Applicable

Validation of Machine Learning Based Personalized Nutrition Algorithm to Reduce Postprandial Glycemic Excursions Among North American Individuals With Newly Diagnosed Type 2 Diabetes

NYU Langone Health1 site in 1 country22 target enrollmentJune 30, 2017
ConditionsType2 Diabetes

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Type2 Diabetes
Sponsor
NYU Langone Health
Enrollment
22
Locations
1
Primary Endpoint
Observed Incremental Area Under the Curve (iAUCobs)
Status
Terminated
Last Updated
5 years ago

Overview

Brief Summary

This is an initial validation study of the Personal Nutrition Project (PNP) algorithm in a North American population with recently diagnosed Type 2 Diabetes (T2D). This is a 2-stage, single-group feeding study in 20 individuals, including 10 participants managed with lifestyle alone, and 10 managed with lifestyle plus metformin.

Detailed Description

The PNP algorithm, which uses a machine learning algorithm to predict postprandial glycemic, may be efficacious for generating tailored dietary advice to moderate the participant's glycemic response to food.

Registry
clinicaltrials.gov
Start Date
June 30, 2017
End Date
January 31, 2018
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age \>21 years to \<70 years
  • Diagnosed with T2DM within 2 years with an HbA1c\<7%
  • Diabetes management by metformin or lifestyle intervention
  • Fasting C-peptide ≥ 0.5 mg/mL (0.17 nmol/L) (to exclude those for whom hyperglycemic exposure is driven by β-cell failure rather than dietary behaviors, as well as those requiring escalation of the medication regime)
  • Ownership a smart phone and are willing to use it to monitor multiple factors influencing glycemic response to glycemia (e.g., sleep, physical activity, diet, stress, medication, and hunger)

Exclusion Criteria

  • are unable or unwilling to provide informed consent;
  • are unable to participate meaningfully in an intervention that involves self-monitoring using software available in English (e.g., due to uncorrected sight impairment, illiterate, non-English-speaking, dementia);
  • are pregnant, are currently trying to become pregnant, or who become pregnant during the study
  • are institutionalized (e.g., in a nursing home or personal care facility, or those who are incarcerated and have limited control over self-management)
  • have had or are planning to have bariatric surgery during the study
  • have a history of heart disease, kidney disease, or retinopathy (to rule-out those with long-standing, undiagnosed T2D)
  • those with an active infection requiring antibiotics in the last 3 months or who develop an active infection requiring antibiotics during the study;
  • those who use acetaminophen and are unwilling or unable to discontinue its use during the study (acetaminophen affects CGM accuracy)39
  • immunosuppressive drugs within three months prior to participation and
  • Chronically active inflammatory or neoplastic disease in the three years prior to enrollment.

Outcomes

Primary Outcomes

Observed Incremental Area Under the Curve (iAUCobs)

Time Frame: 2 Hours

Observed incremental area under the curve (iAUCobs) at 2 hours following each meal and snack will be evaluated via CGM using the Abbott Freestyle Libre Pro, which captures interstitial glucose every 5 minutes. A sensor is inserted into the participant's upper arm. Participants will be blinded to glycemia tracings.

Study Sites (1)

Loading locations...

Similar Trials